West Pharmaceutical Services Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" West Pharmaceutical Services stock.
View analyst ratings for West Pharmaceutical Services or view top-rated stocks.

2 analysts have issued 1 year price targets for West Pharmaceutical Services' shares. Their WST stock forecasts range from $475.00 to $475.00. On average, they expect West Pharmaceutical Services' stock price to reach $475.00 in the next twelve months. This suggests a possible upside of 54.4% from the stock's current price.
View analysts' price targets for West Pharmaceutical Services or view top-rated stocks among Wall Street analysts.

West Pharmaceutical Services' stock was trading at $469.01 at the start of the year. Since then, WST stock has decreased by 34.4% and is now trading at $307.74.
View the best growth stocks for 2022 here.

West Pharmaceutical Services saw a decline in short interest in May. As of May 31st, there was short interest totaling 728,100 shares, a decline of 14.4% from the May 15th total of 850,700 shares. Based on an average daily volume of 423,300 shares, the short-interest ratio is currently 1.7 days. Currently, 1.0% of the company's shares are short sold.
View West Pharmaceutical Services' Short Interest.

West Pharmaceutical Services is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for West Pharmaceutical Services.

West Pharmaceutical Services, Inc. (NYSE:WST) posted its earnings results on Thursday, April, 28th. The medical instruments supplier reported $2.30 EPS for the quarter, topping analysts' consensus estimates of $2.18 by $0.12. The medical instruments supplier had revenue of $720 million for the quarter, compared to the consensus estimate of $720.92 million. West Pharmaceutical Services had a net margin of 23.76% and a trailing twelve-month return on equity of 30.33%. The business's revenue was up 7.4% compared to the same quarter last year. During the same period last year, the business earned $2.05 EPS.
View West Pharmaceutical Services' earnings history.

West Pharmaceutical Services announced a quarterly dividend on Thursday, April 28th. Shareholders of record on Wednesday, July 20th will be given a dividend of $0.18 per share on Wednesday, August 3rd. This represents a $0.72 annualized dividend and a yield of 0.23%. The ex-dividend date is Tuesday, July 19th.
View West Pharmaceutical Services' dividend history.

West Pharmaceutical Services(NYSE:WST) pays an annual dividend of $0.72 per share and currently has a dividend yield of 0.23%. West Pharmaceutical Services has been increasing its dividend for 29 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of West Pharmaceutical Services is 8.00%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, West Pharmaceutical Services will have a dividend payout ratio of 6.99% next year. This indicates that West Pharmaceutical Services will be able to sustain or increase its dividend.
View West Pharmaceutical Services' dividend history.

West Pharmaceutical Services issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of $9.30-$9.45 for the period, compared to the consensus earnings per share estimate of $9.28. The company issued revenue guidance of $3.05 billion-$3.08 billion, compared to the consensus revenue estimate of $3.07 billion.

107 employees have rated West Pharmaceutical Services CEO Eric M. Green on Glassdoor.com. Eric M. Green has an approval rating of 75% among West Pharmaceutical Services' employees. 60.0% of employees surveyed would recommend working at West Pharmaceutical Services to a friend.

Some companies that are related to West Pharmaceutical Services include Align Technology (ALGN), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), QuidelOrtho (QDEL), ICU Medical (ICUI), Haemonetics (HAE), STAAR Surgical (STAA), Merit Medical Systems (MMSI), Neogen (NEOG), Meridian Bioscience (VIVO), Atrion (ATRI), Cerus (CERS), Antares Pharma (ATRS), Anika Therapeutics (ANIK) and Utah Medical Products (UTMD).
View all of WST's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other West Pharmaceutical Services investors own include NVIDIA (NVDA), Johnson & Johnson (JNJ), AbbVie (ABBV), Walt Disney (DIS), Home Depot (HD), Visa (V), Alibaba Group (BABA), McDonald's (MCD), Netflix (NFLX) and PepsiCo (PEP).

West Pharmaceutical Services trades on the New York Stock Exchange (NYSE) under the ticker symbol "WST."

Shares of WST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of WST stock can currently be purchased for approximately $307.74.

West Pharmaceutical Services (NYSE:WST) has a market capitalization of $22.80 billion and generates $2.83 billion in revenue each year. The medical instruments supplier earns $661.80 million in net income (profit) each year or $9.00 on an earnings per share basis.

West Pharmaceutical Services employs 10,065 workers across the globe.

West Pharmaceutical Services was founded in 1923.

West Pharmaceutical Services' mailing address is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. The official website for West Pharmaceutical Services is www.westpharma.com. The medical instruments supplier can be reached via phone at (610) 594-2900, via email at quintin.lai@westpharma.com, or via fax at 800-345-9800.